The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Liposome-based drug delivery in breast cancer treatment
Open accessAbstract
Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels. Liposomal anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs represent an integration of biological components capable of tumor recognition with delivery technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Self-citationNeedham, D., Anyarambhatla, G., Kong, G., & Dewhirst, M. W. (2000) · PubMed · Cited by 746
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Self-citationGill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Self-citationRanson, M. R., Carmichael, J., O'Byrne, K., Stewart, S., Smith, D., & Howell, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3185 · Cited by 293
Development of anti-p185HER2 immunoliposomes for cancer therapy.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., & Wood, W. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1327 · Cited by 258
Self-citationBerry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., Patek, A., & Martin, F. J. (1998) · Annals of Oncology · doi:10.1023/a:1008216430806 · Cited by 241
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., & Gabizon, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990701)86:1<72::aid-cncr12>3.0.co;2-1 · Cited by 213
Anti-HER2 immunoliposomes for targeted therapy of human tumors
Park, J. W., Hong, K., Kirpotin, D. B., Meyer, O., Papahadjopoulos, D., & Benz, C. C. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00326-1 · Cited by 130
Self-citationImmunoliposomes for Cancer Treatment
Park, J. W., Hong, K., Kirpotin, D. B., et al. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60146-5 · Cited by 115
Self-citationAntitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li, C., Price, J. E., Milas, L., Hunter, N. R., Shi, K., Yu, D. F., Charnsangavej, C., & Wallace, S. (1999) · PubMed · Cited by 114
Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.
Cabanes, A., Briggs, K., Gokhale, P. C., Treat, J., & Rahman, A. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.5.1035 · Cited by 103
Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas.
Matteucci, M. L., Anyarambhatla, G., Rosner, G. L., Azuma, C., Fisher, P. E., Dewhirst, M. W., Needham, D., & Thrall, D. Ε. (2000) · PubMed · Cited by 96
Cited by
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Metadata
- Authors
- Park, J. W.
- Venue
- Breast Cancer Research
- Published
- 2002-06
- Volume
- 4
- Issue
- 3
- Pages
- 95-9
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1492185019
- Cited by
- 469
- References
- 19
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.